{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:14:24Z","timestamp":1791342864394,"version":"4.3.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40261-025-01432-z","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:54:04Z","timestamp":1743400444000},"page":"271-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An Overview of Isavuconazole Clinical Use: A Multicentre Analysis of Indications, Exposure and Hepatic Safety"],"prefix":"10.1007","volume":"45","author":[{"given":"Anne-Lise","family":"Bienvenu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Duffour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Chatron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Mrozek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Foroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Lukaszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Merveilleux-du-Vignaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Portran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Parant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Vial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Molu\u00e7on-Chabrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Rascle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Pradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-2932","authenticated-orcid":false,"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1432_CR1","doi-asserted-by":"crossref","unstructured":"Brown GD, Ballou ER, Bates S, Bignell EM, Borman AM, Brand AC, et al. The pathobiology of human fungal infections. Nat Rev Microbiol. 2024;22:687\u2013704.","DOI":"10.1038\/s41579-024-01062-w"},{"key":"1432_CR2","doi-asserted-by":"crossref","unstructured":"Wu Y-J. Chapter 1 - Heterocycles and medicine: a survey of the heterocyclic drugs approved by the U.S. FDA from 2000 to present. In: Gribble GW, Joule JA, editors. Progress in heterocyclic chemistry [Internet]. Elsevier; 2012 [cited 2024 Jul 18]. p 1\u201353. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780080968070000014. Accessed March 22, 2025.","DOI":"10.1016\/B978-0-08-096807-0.00001-4"},{"key":"1432_CR3","unstructured":"Cresemba | European Medicines Agency [Internet]. [cited 2023 Dec 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cresemba. Accessed March 22, 2025."},{"key":"1432_CR4","doi-asserted-by":"publisher","first-page":"e00177","DOI":"10.1128\/aac.00177-22","volume":"66","author":"JS Lewis","year":"2022","unstructured":"Lewis JS, Wiederhold NP, Hakki M, Thompson GR. New perspectives on antimicrobial agents: isavuconazole. Antimicrob Agents Chemother. 2022;66:e00177-e222.","journal-title":"Antimicrob Agents Chemother"},{"key":"1432_CR5","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1128\/AAC.02942-15","volume":"60","author":"A Desai","year":"2016","unstructured":"Desai A, Schmitt-Hoffmann A-H, Mujais S, Townsend R. Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment. Antimicrob Agents Chemother. 2016;60:3025\u201331.","journal-title":"Antimicrob Agents Chemother"},{"key":"1432_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760\u20139.","journal-title":"Lancet"},{"key":"1432_CR7","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/jac\/dkae103","volume":"79","author":"R Lewis","year":"2024","unstructured":"Lewis R, Niazi-Ali S, McIvor A, Kanj SS, Maertens J, Bassetti M, et al. Triazole antifungal drug interactions\u2014practical considerations for excellent prescribing. J Antimicrob Chemother. 2024;79:1203\u201317.","journal-title":"J Antimicrob Chemother"},{"key":"1432_CR8","doi-asserted-by":"crossref","unstructured":"Erg\u00fcn M, Jansen AME, Hilbrands LB, de Kort E, Kunst H, Reijers MHE, et al. Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. J Antimicrob Chemother. 2024;79:1801\u201310","DOI":"10.1093\/jac\/dkae139"},{"key":"1432_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jac\/dkae037","volume":"79","author":"M Mikulska","year":"2024","unstructured":"Mikulska M, Melchio M, Signori A, Ullah N, Miletich F, Sepulcri C, et al. Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring. J Antimicrob Chemother. 2024;79:835\u201345.","journal-title":"J Antimicrob Chemother"},{"key":"1432_CR10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"1432_CR11","unstructured":"The use of the WHO-UMC system for standardised case causality assessment [Internet]. [cited 2024 Jul 18]. Available from: https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment. Accessed March 22, 2025."},{"key":"1432_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/jof8010074","volume":"8","author":"H Dagher","year":"2022","unstructured":"Dagher H, Hachem R, Chaftari A-M, Jiang Y, Ali S, Deeba R, et al. Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant. J Fungi (Basel). 2022;8:74.","journal-title":"J Fungi (Basel)."},{"key":"1432_CR13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/myc.12910","volume":"62","author":"H Hassouna","year":"2019","unstructured":"Hassouna H, Athans V, Brizendine KD. Real-world use-Isavuconazole at a large academic medical center. Mycoses. 2019;62:534\u201341.","journal-title":"Mycoses"},{"key":"1432_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14045","volume":"25","author":"SA Scott","year":"2023","unstructured":"Scott SA, Perry C, Mahmoudjafari Z, Martin GA, Boyd S, Thompson J, et al. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole. Transplant Infectious Dis. 2023;25: e14045.","journal-title":"Transplant Infectious Dis"},{"key":"1432_CR15","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/cid\/ciz159","volume":"69","author":"AJ DiPippo","year":"2019","unstructured":"DiPippo AJ, Kontoyiannis DP. Lack of toxicity with long-term isavuconazole use in patients with hematologic malignancy. Clin Infect Dis. 2019;69:1624\u20137.","journal-title":"Clin Infect Dis"},{"key":"1432_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107070","volume":"144","author":"P Monz\u00f3-Gallo","year":"2024","unstructured":"Monz\u00f3-Gallo P, Lopera C, Bad\u00eda-Tejero AM, Machado M, Garc\u00eda-Rodr\u00edguez J, Vidal-Cort\u00e9s P, et al. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients. Int J Infect Dis. 2024;144: 107070.","journal-title":"Int J Infect Dis"},{"key":"1432_CR17","doi-asserted-by":"publisher","first-page":"ofaw223","DOI":"10.1093\/ofid\/ofae223","volume":"11","author":"J Couchepin","year":"2024","unstructured":"Couchepin J, Reinhold I, Kronig I, Guidi M, Buclin T, Schreiber PW, et al. Isavuconazole for the treatment of fungal infections: a real-life experience from the Fungal Infection Network of Switzerland (FUNGINOS). Open Forum Infect Dis. 2024;11:ofaw223.","journal-title":"Open Forum Infect Dis"},{"key":"1432_CR18","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3390\/pharmaceutics13122099","volume":"13","author":"PG Cojutti","year":"2021","unstructured":"Cojutti PG, Carnelutti A, Lazzarotto D, Sozio E, Candoni A, Fanin R, et al. Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles? Pharmaceutics. 2021;13:2099.","journal-title":"Pharmaceutics"},{"key":"1432_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jac\/dky463","volume":"74","author":"T Kaindl","year":"2019","unstructured":"Kaindl T, Andes D, Engelhardt M, Saulay M, Larger P, Groll AH. Variability and exposure\u2013response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother. 2019;74:761\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"1432_CR20","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","volume":"74","author":"E Furfaro","year":"2019","unstructured":"Furfaro E, Signori A, Di Grazia C, Dominietto A, Raiola AM, Aquino S, et al. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob Chemother. 2019;74:2341\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1432_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/pharmaceutics15010075","volume":"15","author":"H Elhence","year":"2022","unstructured":"Elhence H, Mongkolrattanothai K, Mohandas S, Neely MN. Isavuconazole pharmacokinetics and pharmacodynamics in children. Pharmaceutics. 2022;15:75.","journal-title":"Pharmaceutics"},{"key":"1432_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","volume":"44","author":"MJ Dolton","year":"2014","unstructured":"Dolton MJ, McLachlan AJ. Voriconazole pharmacokinetics and exposure\u2013response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents. 2014;44:183\u201393.","journal-title":"Int J Antimicrob Agents"},{"key":"1432_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/phar.1779","volume":"36","author":"Y Wang","year":"2016","unstructured":"Wang Y, Wang T, Xie J, Yang Q, Zheng X, Dong W, et al. Risk factors for voriconazole-associated hepatotoxicity in patients in the intensive care unit. Pharmacotherapy. 2016;36:757\u201365.","journal-title":"Pharmacotherapy"},{"key":"1432_CR24","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40262-023-01305-8","volume":"62","author":"AME Jansen","year":"2023","unstructured":"Jansen AME, Mertens B, Spriet I, Verweij PE, Schouten J, Wauters J, et al. Population pharmacokinetics of total and unbound isavuconazole in critically ill patients: implications for adaptive dosing strategies. Clin Pharmacokinet. 2023;62:1701\u201311.","journal-title":"Clin Pharmacokinet"},{"key":"1432_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/myc.13653","volume":"66","author":"R Bertram","year":"2023","unstructured":"Bertram R, Naumann H-T, Bartsch V, Hitzl W, Kinzig M, Haarmeyer G-S, et al. Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19. Mycoses. 2023;66:1071\u20138.","journal-title":"Mycoses"},{"key":"1432_CR26","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.3390\/jcm11195756","volume":"11","author":"L Bolcato","year":"2022","unstructured":"Bolcato L, Thiebaut-Bertrand A, Stanke-Labesque F, Gautier-Veyret E. Variability of isavuconazole trough concentrations during longitudinal therapeutic drug monitoring. JCM. 2022;11:5756.","journal-title":"JCM"},{"key":"1432_CR27","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.2147\/IDR.S434622","volume":"16","author":"N Chen","year":"2023","unstructured":"Chen N, Wang X, Li Y, Yang P, Huang M, Lu X. Population pharmacokinetics of isavuconazole in adult: a systematic review. IDR. 2023;16:7559\u201368.","journal-title":"IDR"},{"key":"1432_CR28","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","volume":"43","author":"EK McCreary","year":"2023","unstructured":"McCreary EK, Davis MR, Narayanan N, Andes DR, Cattaneo D, Christian R, et al. Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy. 2023;43:1043\u201350.","journal-title":"Pharmacotherapy"},{"key":"1432_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00829-23","volume":"67","author":"B Fern\u00e1ndez Ledesma","year":"2023","unstructured":"Fern\u00e1ndez Ledesma B, Mendoza-Palomar N, Melendo P\u00e9rez S, Fern\u00e1ndez-Polo A, Renedo Mir\u00f3 B, Pau Parra A, et al. Isavuconazole use and TDM in real-world pediatric practice. Antimicrob Agents Chemother. 2023;67: e0082923.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01432-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01432-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01432-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:45:17Z","timestamp":1746621917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01432-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01432-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"2 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Hospices Civils de Lyon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sylvain Goutelle is an Editorial Board member of Clinical Drug Investigation. Sylvain Goutelle was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This was a non-interventional study with no additional procedure. Data were collected during routine patient care. This study was conducted in accordance with the Declaration of Helsinki and national and institutional standards. This study was approved as an evaluation of professional practices by the Quality department of Lyon university hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Due to the retrospective nature of the study, formal consent was not required. Electronic records were under the auspice of the French National Committee for Data Protection and Freedom of Information (N\u00b023\u2013138).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are not openly available due to protect study participant privacy.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"ALB, SG, and LF, designed the work. AD, AH, ALB, CC, CM, CMC, HLW, NM, PP, PR, and ACL, contributed to data acquisition. ALB, AM, FP, PP, SG, and TV, contributed to data analysis. ALB and AD wrote the original draft. All authors reviewed the manuscript critically and approved the final version. All authors agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}